醫藥 - BTBA 8/5-6 哈佛中醫藥論壇8/6


Boston Taiwanese Biotechnology Symposium is held by Boston Taiwanese Biotechnology Association (BTBA), a non-profit organization established by Taiwanese professionals in biology-related fields in 2012 in Boston. We strive to bridge the academics and industry gap in the U.S. and Taiwan and to meet the needs of professionals in biology-related fields.
This year, we are honored to introduce Dr. Lily Y. Jan (Professor of UCSF; member of National Academy of Sciences and Academia Sinica) and Dr. James C. Liao (President of Academia Sinica; member of National Academy of Sciences and Academia Sinica) as our keynote speakers.
Highlights of our program include:
  • Panelists from both academia and industry to discuss the latest research, potential applications, and clinical development of “CRISPR technology” and “Immunotherapy”.
  • A new session on “Advancing your career” to learn about leadership and people skills, and how to exercise those skills and plan strategically to develop and establish a successful career in academia and industry.
  • A new session on “Commercialization of life innovation” to learn about technology transfer, the role of venture capital, and more about entrepreneurship.
  • Academic panelists from the U.S. to share their experience in research and career path in Academia.
  • Explore and build your career path in biotech or pharma by connecting with people from diverse fields.
  • Meet researchers from Academia Sinica. You may submit your CV to be considered in 1-on-1 setting.
  • Roundtable lunch with panelists
The annual meeting aims to provide platforms for interactions among young professionals, postdocs and students to share experiences and learn insight in diverse bio-related career paths.

Symposium program can be found on our website: http://btbatw.org/2017

19th SAPA-NE AC Brochure


Greetings from Conference Chair

Dear SAPA Members and Friends:

On behalf of the organizing committee, it is my great pleasure to welcome you to the 19th Annual Conference of the Sino-American Pharmaceutical Professionals Association New England (SAPA-NE). SAPA-NE is a non-profit organization founded in 1998 and currently serves more than 2000 pharmaceutical/biotech professionals. Our mission is to serve its members and foster their career development through conference/symposium/networking and to promote exchanges and collaboration across pharmaceutical/biotech industries and academics between China and the US.
Our annual conference is SAPA-NE’s most prestigious event. Every year we bring together leaders from academia and industry, investors and entrepreneurs from around the world to share the cutting-edge discovery, exciting clinical development, and experiences and trends in business and career in life sciences. The theme of this year’s conference is "Convergence: Transformation of Life Sciences in Boston".
Boston is now recognized as the epicenter of innovation for both biologics and small molecules R&D in the world. More than 400 large and small biopharmaceutical companies have established headquarters or research centers here, plus many world-leading hospitals and prestigious universities, among them are Novartis, Pfizer, Sanofi, Biogen, Merck, Astra-Zeneca, AbbVie, Bristol-Myers Squibb, Takeda, Shire, EMD Serono, J&J and Bayer etc., as well as numerous small innovative companies. It’s difficult to fathom that this healthy and thriving ecosystem has not always been here. It started almost 10 years ago deep in the financial crisis that affected global economy. The Life Science Initiative enlisted the input and resources from government agencies, industry leaders, academic institutions, venture capitalists, and law firms. What we have witnessed since is an unprecedented growth in translating research discovery into therapeutic development. The game-changing immunotherapy in cancer treatment, the potential applications of genome editing technology such as CRISPR-Cas9, are just a couple of many areas that local companies are working on. This is the golden area of life sciences innovation, and Boston is the place where it all happens.
There are multi-national pharmaceutical companies overcoming cultural and organizational challenges to locate research centers in Boston area. There are local startups successfully raising capital when the overall trend is less than ideal. There are talented scientists helping accelerate the R&D process by crossing over between academia and industry. Those are the reason behind the theme for this year’s annual conference, to celebrate what makes Boston uniquely attractive to life sciences – the convergence of all the essential elements needed for transformation. This full day event will include plenary sessions, panel discussion, and a dinner reception. Biopharma industry senior executives, Chinese returnee entrepreneurs, and other experts will share their visions on scientific innovation, high-tech entrepreneurship, new trends in R&D globalization and strategies. Local and Chinese companies will bring a variety of job opportunities and set booths to recruit talents.

This year’s annual conference dinner reception is generously supported by our Diamond Partner, Greenberg Traurig, LLC, which is celebrating its 50th Anniversary. A keynote speech titled “Convergence of Law and Biopharma” will be given by Dr. Fang Xie, co-lead of its Biotechnology and Pharmaceutical Group.

Finally, I would like to express my most sincere gratitude towards all the members of the conference organizing committee for their outstanding work and unparalleled dedication in making this event possible. I am also grateful for all our valued sponsors for their generous and continued support. Everybody is welcome to join SAPA-NE and together we build an even stronger community. Thank you!

Sincerely yours,

Larry Cai, MBA, MS.
SAPA-NE 19th Annual Conference Chair
SAPA-NE President Elect 2016-2017

Conference Program
8:00 – 9:00
Registration and Breakfast
Opening Remarks
9:00 – 9:10
Mr. Larry Cai, Conference Chair, SAPA-NE President-Elect
Hon. Deval Patrick, Governor, Massachusetts (2007-2015)
Mr. Jijun Xing, Counselor of S&T, Consulate General of P. R. China
Session 1: Cutting Edge of Biomedical Innovation in Boston
Chairs: Drs. Jun Johnny Yang, Xingfeng Bao, Kejie Li, Lin Lin, Jing Tong
9:10 – 9:45
Dr. Andy Plump, Chief Medical and Scientific Officer, Takeda
“The Future of Drug Discovery: Innovation-driven Research & Development at Takeda”
9:45 – 10:20
Dr. Richard Murray, CEO and President, Jounce Therapeutics
“Immunology meets oncology: breakthroughs in immunotherapy”
10:20 – 10:50
Coffee Break and Exhibition
10:50 – 11:25
Dr. Sven Ante “Bill” Lundberg, CSO, CRISPR Therapeutics
“Bringing CRISPR Therapeutics to the Clinic”
11:25 – 11:50
Dr. Luhan Yang, CSO, eGenesis
“Gene Editing to Transform Xenotransplantation”
11:50 – 12:10
Dr. James Yang, President/CEO of Abpro China
“Fast Road Map for Biologic R&D”
12:10 – 1:00
Lunch and Exhibition
Session 2: Collaborations and Opportunities Across the Ocean
Chairs: Drs. Mangeng Cheng, Dapeng Chen, Haishan Li, and Bing Ma
1:00 – 1:20
Dr. Rich Soll, SVP & Head of International Discovery Services Unit (IDSU)
Enter the Era of Big Data, Deep Learning, and Artificial Intelligence: Capitalizing on a Transformative Opportunity for Drug Discovery”
1:20 – 1:40
Dr. Shidong Jia, Founder & CEO, Predicine Holdings Ltd.
“Precision medicine: clinical application of liquid biopsies in cancer”
1:40 – 2:00
Chaoshe Guo, Ph.D., Vice President and Senior R&D Director, Beijing Biocytogen Co.,Ltd
“Humanized immune checkpoint mouse models and in vivo efficacy studies of I/O drugs”
2:00 – 2:20
Ms. Jane Li, Co-founder, AF Recruiting
“Landscape of Healthcare Job Market in China”
Panel Forum: Collaborations and Opportunities Across the Ocean
Chairs: Drs. Tianxiao Sun and QiYing Hu
2:20 – 3:20
Dr. Shaohui Huang, Zhongshan Tsuihang New District
Dr. Ruhong Jiang, Applied Stemcell
Dr. Jinbo Lee, Scilligence
Dr. John MacDougall, CrownBio
Dr. Weimin Tang, Hengrui Therapeutics Inc.
Dr. Tony Xie, Xiyu Investment Company
3:20 – 3:50
Coffee Break and Exhibition
Session 3: Entrepreneurship and Global Leadership in Biomedical Sciences
Chairs: Mr. Larry Cai, Drs. Guiqing Liang and Jianzhu Chen
3:50 – 4:20
Dr. Lijun Wu, Entrepreneur-in-Residence, Atlas Venture, former SVP, Preclinical & Early Clinical Development, Delinia, Inc
“From Seed to Exit in 15 Months: The Delinia Story”
4:20 – 4:50
Dr. Yinxiang Wang, Chairman, Beijing JacoBio Pharmaceuticals, former CEO & CSO, Zhejiang Betta Pharmaceuticals
“Challenges and Strategies of Innovative Drug R&D in China”
4:50 – 5:25
Dr. Yong-Jun Liu, Head of Research, Global R&D, Sanofi
“Follow the Science and Capture the Opportunities”
5:25 – 5:30
Closing Remark: Dr. Jiang Long, President of SAPA-NE
SAPA-NE 19th Annual Conference Dinner Reception (Ticket Required)
Sponsored by Greenberg & Traurig, LLP
(Location: Samberg Conference Center, 50 Memorial Drive, Cambridge MA)
Chair: Dr. Jiang Long, President of SAPA-NE
6:00 – 6:30

6:30 – 6:35

6:35 – 6:45

6:45 – 7:00

7:00 – 7:10

7:10 – 9:00
GT HomeNetworking

Welcome Remarks
Dr. Jiang Long, President of SAPA-NE

Keynote Speech
Dr. Fang Xie, Co-lead, Global Life Science, Greenburg Traurig, LLP
“Convergence of Law and Biopharma”

SAPA-NE Cooperate Service Award/Service Award Presentations
Dr. Jiang Long and Mr. Larry Cai/ Drs. Bingli Ma, Mark Lin, Xiaotian Zhong, Min Chen

SAPA-NE High School Excellence Scholarship Presentation
Drs. Huo Li and Guiqing Liang


Opening Remark

Honorable Deval Patrick
Governor, Commonwealth of Massachusetts (2007-2015)

Deval 2.jpg

Jijun Xing, Ph.D.
Science and Technology Counselor, Chinese Consulate-General in New York


Session 1: Cutting Edge of Biomedical Innovation in Boston

Andy Plump, MD, PhD Chief Medical and Scientific Officer, Takeda Pharmaceuticals
Presentation title: The Future of Drug Discovery: Innovation-driven Research & Development at Takeda

Richard Murray, Ph.D., Chief Executive Officer and President
Presentation title: Immunology meets oncology: breakthroughs in immunotherapy

Dr. Sven Ante “Bill” Lundberg, Chief Scientific Officer, CRISPR Therapeutics
Presentation title: Bringing CRISPR Therapeutics to the Clinic

LUHAN YANG, Ph.D., Co-Founder and CSO
Presentation title: “Gene Editing to Transform Xenotransplantation

James Yang, Ph.D., President and CEO, Abpro-China
Presentation title: “Fast Road Map for Biologic R&D

Session 2: Collaborations and Opportunities Across the Ocean

Dr. Rich Soll, SVP & Head of International Discovery Services Unit (IDSU)
Presentation title: Enter the Era of Big Data, Deep Learning, and Artificial Intelligence: Capitalizing on a Transformative Opportunity for Drug Discovery

Shidong Jia, Ph.D., Founder & CEO, Predicine Holdings Ltd
Displaying image1.JPGPresentation title: “Precision medicine: clinical application of liquid biopsies in cancer”

Chaoshe Guo, Ph.D., Vice President and Senior R&D Director, Beijing Biocytogen Co.,Ltd
Presentation Title: Humanized immune checkpoint mouse models and in vivo efficacy studies of I/O drugs

Ms. Jane Li,
Co-founder of AF Recruiting
Presentation title: Landscape of Healthcare Job Market in China

Panel Forum: Collaborative Innovation and Partnership

Shaohui Huang, Ph.D., Business Consultant, Zhongshan Tsuihang New District; President & Co-Founder, LightEdge Technologies, Ltd.; Professor, Institute of Biophysics, Chinese Academy of Sciences

Applied StemCell
Ruhong Jiang, Ph.D.,
Co-founder, President and CEO, Applied StemCell, Inc.

Jinbo Lee, Ph.D., Co-founder and Chief Scientific Officer of Scilligence Corporation

John MacDougall, Ph.D., Director of Scientific Engagement, CrownBio

Image result for jiangsu hengrui medicine
Weimin Tang, Ph.D., Head of BD, Jiangsu Hengrui Medicine Co.


Mr. Shuijiang Zhou, Founder, Xiyu Investment Company

Session 3: Entrepreneurship and Global Leadership in Biomedical Sciences

Lijun Wu, Ph.D., Entrepreneur-in-Residence, Atlas Venture, former SVP, Preclinical & Early Clinical Development, Delinia, Inc
Presentation title: “From Seed to Exit in 15 Months: The Delinia Story”

Beijing Jacobio Pharmaceuticals Co.,Ltd
Yinxiang Wang, Ph.D., Chairman, Beijing JacoBio Pharmaceuticals, former CEO & CSO, Betta Pharmaceuticals
Presentation title: Challenges and Strategies of Innovative Drug R&D in China

Dr. Yong-Jun Liu, Head of Research, Global R&D, Sanofi
 Presentation title: Follow the Science and Capture the Opportunities

Dinner Reception Keynote Speech

Dinner Keynote Speaker:
Fang Xie, Ph.D.
Of Counsel, Co-lead, Global Life Sciences, Greenberg Traurig, LLP, Boston

Presentation title: The Convergence of Law and Biopharma”

Diamond Partner


Platinum Partner


Media Partner

Gold Partner


Silver Partner

Applied StemCell https://www.bms.com/content/dam/bms/us/en-us/downloads/BMS-logo.jpg
Image result for jiangsu hengrui medicine logo.png http://www.takeda.us/images/usr/default/header_logo_ci.jpg

Event Partner
http://www.aberjonalabs.com/images/header.jpg Achemtek

Logo Image result

Beijing Jacobio Pharmaceuticals Co.,Ltd
China CRO Company,Preclinical research services
Selleck Chemicals Logo https://www.wyzerbio.com/wiser/image/top-banner.jpg

Directions to Tang Center
Address: Tang Centrer, 70 Memorial Drive, Cambridge, MA 02142
Due to construction activities in the area, many parking lots are no longer available. It is highly recommended to carpool or to take public transportation to the event. The closest subway station (T) is Kendall Square stop (Red-line).
Parking (important notice!)
There is a small parking lot (E51 lot) for Tang Center with limited number of spaces shown in the map below. Also, there are several public parking lots or garages in Kendall Square area in walking distance to Tang Center.
One closest parking garage (3 blocks walking distance to Tang Center) is shown below:
Kendall Square South Garage ($11 on Saturday), 350 Kendall St, Cambridge, MA 02142


19th SAPA-NE Annual Conference

         June 17, 2017@MIT

        广  欢  阵  药

        积  迎  容  协

        人  参  强  年

        脉  加  大  会

Registration link:


Registration to 19th SAPA-NE Annual Conference 2017

19th SAPA-NE Annual Conference 2017

Date: 9:00 am - 6:00 pm (Conference), Saturday, Jun 17th, 2017
Dinner Event: 6:30 pm - 9:30 pm, Saturday, Jun 17th, 2017
Location: MIT Sloan School of Management, Tang Center, Wong Auditorium, Cambridge, MA

Free for all active SAPA-NE members and MIT students
$15 for students and postdoctoral fellows
$30 for all other participants
Thank you for your donation to SAPA-NE. Please fill in all the information.
This donation is not refundable.Thank you.

Confirmed Speakers:

Andrew “Andy” Plump, M.D., Ph.D., Chief Medical and Scientific Officer, Takeda 

Yong-Jun Liu, Ph.D., Head of Research, Global R&D, Sanofi

Richard Murray, Ph.D., Chief Executive Officer and President, Jounce Therapeutics 

Sven Ante “Bill” Lundberg, Ph.D., Chief Scientific Officer, CRISPR Therapeutics 

Yinxiang Wang, Ph.D., Chief Executive Officer, Jacobio Pharmaceuticals, Co-found of Betta Pharma 

Lijun Wu, Ph.D., Entrepreneur-in-Residence, Atlas Ventures, SVP at Delinia (now Celgene) 

Luhan Yang, Ph.D., Co-founder and Chief Scientific Officer, eGenesis 

James (Jianguo) Yang, Ph.D., President & CEO, Abpro-China Shidong Jia, Ph.D., Founder & CEO, Predicine Holdings Ltd

Traditional Chinese Medicine Forum-HMS

Time: 9:00am-6:00pm Sunday August 6, 2017

Place: Harvard Medical School, McLean Hospital, 115 Mill Street, Belmont,

MA 02478 FRANCIS de MARNEFFE (cafeteria)

Parking: Free 
CEUs (Continue Education Credit): 9 credits

Fee (lunch included): 

Need 9 CEU Credits: $130 for MSCM members; $180 for non-members

Free for Dr. Lee’s group, Harvard Faculty/Fellow (Please contact us, reservation needed)

Sponsored: Massachusetts Society of Chinese Medicine (MSCM)

Alternative Medicine Center, McLean Hospital, HMS

9:00-9:15am Registration

9:15-12:30pm “针灸治疗花粉过敏症临床观察及特效针法演示”
Acupuncture for the treatment of seasonal allergies 
& Special techniques Demo

12:30-2:00pm Lunch & discussion

2:00pm-6:00pm “常用针刺手法实际操作技巧临床应用研究”
Clinical use of acupuncture techniques and Demo

Speaker: 纽约著名的中医专家林榕生博士, Dr. Rongsheng Lin

Call Dr. Li 617 323 7809 or 
一 简介: 林榕生: 纽约著名中医专家,中医针灸博士,主任医师,现为世界中医药学会联合会副主席、国际中医药专业高级技术职称评审委员会委员、世中联骨伤科、外治方法研究及穴位埋线等专业委员会副会长;世界针灸学会联合会执委、世针联中医针灸传承工作委员会副主任委员、美国中医药学会董事局主席,福建中医药大学美国校友会会长,美国大纽约中医针灸学会总顾问、全美华裔中医组织联合会副主席,国际中医药联盟美容养生专家委员会副主任委员,福建中医药大学等多所大学以及中国全军针灸培训中心客座教授,联合国教科文组织人类非物质文化遗产代表作名录中医针灸代表性传承人张缙教授亲传入室弟子。




 2017-04-11 Jo Lee CABA

“Boston BioForum 2017”
CABA10th Annual Conference
Coming Soon!!!
🏨Boston Marriott Newton
📍2345 Commonwealth Ave, Newton, MA 02466
🕙10:00 AM to 6:00 PM on Saturday, May 6, 2017.


Gordon Freeman

Professor at Harvard University

Carmen Bozic, MD
Carmen Bozic MD is Senior Vice President of Global Development at Biogen, accountable for developing, obtaining and maintaining regulatory approval of therapies in Biogen’s therapeutic focus areas of Neurodegenerative and Rare Diseases. Dr. Bozic is an experienced drug development leader with 18 years of progressively increasing responsibilities in the biopharmaceutical industry.
Kenneth I Kaitin, Ph.D.
Dr. Kaitin is Professor of Medicine and Director of the Tufts Center for the Study of Drug Development at Tufts University School of Medicine. Dr. Kaitin alsoholds appointments as Advisory Professor at Shanghai Medical College of Fudan University in China; Visiting Executive at the Tuck School of Business at Dartmouth College; and faculty of the European Center for Pharmaceutical Medicine at the University of Basel.
Ken LeClair, Ph.D.
Ken LeClair received his undergraduate degree from BowdoinCollege and a Ph.D. in Immunobiology from Yale University.
He did a postdoc at the MIT Center for Cancer Research andhad an academic appointment as Assistant Professor of Medicine in theImmunology Division of the Beth Israel Deaconess Medical Center at the Harvard Medical School.
He joined Editas Medicine late in 2016 and is working to help bring CRISPR-based therapies to the clinic and to market.
Samarth Kulkarni, Ph.D.
Samarth(Sam) Kulkarni is the Chief Business Officer of CRISPR Therapeutics since 2015.  At CRISPR, Sam is responsible for Corporate Strategy, Business Development, and Investor Relations. Sam has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. 
Xinyu Weng, Ph.D.
Weng, Xinyu, Ph.D, is First Secretary of the Embassy of the People’s Republic of China to the United States of America. As the primary point ofcontact for China Food and Drug Administration (CFDA) in the U.S., Dr. Weng is committed to strengthening bilateral food and drug regulatory cooperation between China and the U.S., and reaching out to the U.S. food and drug industry.
Lynn Yang, MBA
Lynn Yang, focusing on healthcare investment. Prior to joining Sequoia Capital in May,2015, Lynn worked at Legend Capitalhealthcare team. Lynn accomplished investment deals in different area of healthcare industry. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product managerat GE Healthcare.  
Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.
Jason Fisherman, MD, MBA
Jason is an investor in medical innovation, drug developer, and company founder. He has worked to build life science companies as a managing director at the global private equity firm Advent International and subsequently as co- founder of the venture spin-out Synthesis Capital. Jason has funded more than thirty companies that have brought over ten new products to market.
James (Jianguo) Yang, Ph.D.
Dr. James (Jianguo) Yang has over 20-year extensive experience in biopharma industry. Currently, Dr. Yang is President / CEO Abpro-China. Before joining Abpro, Dr. Yang was CSO / VP Biologics in Qilu Pharmaceuticals, and also had scientific leadership positions in Abbott Lab Pharma Division, MedImmune /Astra Zeneca, and Genzyme / Sanofi.

Junzhi (John) Yao, Ph.D.
Dr. Junzhi (John) Yao received his PhD degree in chemistry from Wuhan University. He joined Medicure Inc. in Winnipeg, Canada as a Research Scientist conducting drug discovery research for cardiovascular diseases and stroke.

In 2009, Dr. Yao co-founded TC Scientific Inc. in Edmonton, Alberta, Canada, which has become one of the top CROs in Canada.
Hui Cai, Ph.D.
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances,and Head of PR and Corporate Communications.
Prior to WuXi, Dr. Cai spent 10 years at Johnson& Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmunediseases.


09:00 - 10:00 am      Registration / Social and Networking
10:00 - 10:05 am      Opening Remarks, Conference Chair
10:05 - 10:15 am      Introduction of CABA, President, CABA
Featured Speaker
10:15 - 11:00 am       Kenneth I. Kaitin,Ph.D., “The Global Landscape for Pharmaceutical R&D: Current Trends -Future Opportunities”
Session I -Immunotherapy: for the Cure ofCancer
11:00 - 11:35 am       Samarth Kulkarni,Ph.D. “CRISPR-based Therapeutics:  Making it a Reality in Asian Markets”
11:35 - 12:10 pm       Ken LéClair, “Development of Cell and Gene-edited Products”
LUNCH AND VENDOR SHOW: 12:10 - 1:30 pm (LunchProvided on Site)
12:45 - 1:15 pm  TC Scientific Presentation, John Yao, "A CRO's View of the Pharma Landscape"
SESSION II – Innovation,Investment, and Entrepreneurship
1:30 - 2:05 pm          Hui Cai, Ph.D. Wuxi (TBD ,)
2:05 - 2:40 pm          James Yang, Ph.D. “StrategicPartnership for Success in Biologics
2:40 - 3:15 pm           Lynn Yang, MBA, Sequoia Capital “Sequoia China HealthcareInvestment Strategy”
3:15 - 3:50 pm           COFFEE BREAK AND VENDOR SHOW
SESSION III - CFDA Regulatory reform and Innovation for the benefit ofPatients           
3:50 - 4:25 pm           Jason Fisherman, M.D.(TBD)
4:25 - 5:00 pm           XinYu Weng, Ph.D; MBA. “Overview onCFDA Drug Regulatory Reform”    
5:00 - 5:35 pm           Carmen Bozic, M.D. SVP GlobalDevelop. “Innovations in Intrathecal Antisense Oligonucleotide Therapy forNeurological Diseases”
5:35 - 6:00 pm          Closing Remarks and Networking
Link: http://caba-annualmeeting-2017.eventdove.com


时   间
地   点
主   办
承   办
协  办
Humphries Pharmaceutical Consulting, LLC


HKS Science + Innovation Diplomacy Symposium
The HKS Science + Innovation Diplomacy Symposium aims to put a spotlight on the intersection of Science and innovation with diplomacy and how these two elements act as drivers for solutions to foreign policy challenges.
The Science + Innovation Diplomacy Symposium will provide a space for a trilateral exchange between Academia, Policy makers and the Private Sector to discuss “common ground” where science and innovation can be used as a bridge between governments and people.
Saturday, April 15, 2017 | 9:00AM - 3:30PM
Starr Auditorium, 5th Floor, Belfer Building
79 John F. Kennedy Street
Cambridge, MA, 02138
This event is free and open to the public. As space is limited for this event, RSVPs will be accepted on a first come, first served basis.

At the Harvard T.H. Chan School of Public Health on Friday, April 7th for the 2017 Health Equity & Leadership Conference themed “Advocacy and Leadership for Health Equity.”

Closing keynote: Dr. Elisa Choi, Chairperson of the Commonwealth of MA Asian American Commission

Tickets are FREE and open to all. PLEASE REGISTER in advance through Eventbrite to ensure entry, as space is limited. Lunch and refreshments are included!

REGISTER HERE: http://bit.ly/2n5Raly

HEAL was formed in 2012 by a group of students at the Harvard T.H. Chan School of Public Health dedicated to generating discourse and action to resolve issues related to health inequities in the Boston and Cambridge communities. This year we aim to expand our scope to discuss how we can address health equity in a new administration from grassroots organizing to lobbying policymakers. We seek to foster a conversation between community members, students, and faculty about the causes of inequities, the role of community organizations in serving vulnerable populations, and innovative solutions for a more equitable future.

Featured speakers and panelists include:
* Thaddeus Miles, Director of Community Services at MassHousing)
* Dr. Benjamin Cook, Director of the Health Equity Research Lab and the Center for Multicultural Mental Health Research
* Eva Stahl, Director at Community Catalyst Children's Health Project
* Ashley Slay, Boston Area Rape Crisis Center
* Irvienne Goldson, Deputy Director of ABCD Health Services
* Dr. Nancy Oriol and Jennifer Bennet, Executive Director of The Family Van
and more to be announced!

See below for a tentative conference agenda:
*subject to changes*

8:30am - 9:30am- Registration & Breakfast
9:30am -10:20am- Opening Remarks
10:30am -12:20pm- Panels
- Panel #1 - Advocating for Health Equity: Translating Research & Policy into Action
- Panel #2 - Community-Based Approaches to Health Equity
12:30-1:30PM- Lunch
1:30pm-2:20pm- Workshops Session #1
- Grassroots Organizing
- Advocating for Health Equity in a Clinical Setting
- Negotiation and Conflict Resolution
2:30pm-3:20pm- Workshop Session 2:
- Negotiation and Conflict Resolution
- Public Speaking
- Social Entrepreneurship and Innovation
- Grassroots Organizing
3:30pm-4:30pm Closing Keynote

Traditional Chinese Medicine Forum-HMS

Time: 9:00am-5:00pm Sunday May 21, 2017
Place: McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478 FRANCIS de MARNEFFE (cafeteria)
Parking: Free 

CEUs (Continue Education Credit): 9 credits
Fee (lunch included): 
Need 8 CEU Credits: $90 for MSCM members; $120 for non-members
No CEU, Free for Dr. Lee’s group, Harvard employee (reservation needed)
Sponsored: Massachusetts Society of Chinese Medicine (MSCM)
Alternative Medicine Center, McLean Hospital, HMS


9:00-9:15am Registration
9:15-12:00pm Integration of Stretching motion and Tuina with Acupuncture
12:00-1:30pm Lunch & discussion
1:30pm-5:00pm Holistic approach in treating neuroendocrine disorders
Speaker: Dr. Jing Liu, PhD, L.Ac

Call Dr. Li 617 323 7809 or 

Allurion Repays Massachusetts Life Sciences Center
Natick company has commercialized a gastric balloon technology
to combat obesity

Natick, MA - The Massachusetts Life Sciences Center (MLSC) and Natick-based Allurion Technologies announced today that the company, which was awarded a $750,000 Accelerator loan from the MLSC in 2011, has repaid the loan with interest after a successful funding round from private investors. Allurion’s repayment to the MLSC totaled $1,115,824.

Allurion’s flagship product is the Elipse™ gastric balloon, a procedureless™ medical device for weight loss.  The Elipse device comprises a balloon made of thin polymer film that is delivered in a 15-minute outpatient visit without need for anesthesia or surgery.  It is filled with water and resides in the stomach for four months, enabling weight loss which averages between 10% and 15% of starting weight.  At the end of therapy, a patented opening mechanism is automatically activated, allowing the device to empty and pass naturally.

At the time of the MLSC loan Allurion had three employees and was still developing its technology.  The company now has more than 20 Massachusetts-based employees.  Its product, which has not yet been approved by the FDA, is currently available in select weight loss centers in France, Italy, Belgium, Greece, the U.K., Spain, Kuwait, Saudi Arabia and Qatar, with plans for a U.S. clinical trial commencing in 2017.

Allurion has also served as a host company for the MLSC's Internship Challenge Program, hosting seven interns to date for which it has or will receive salary reimbursement through the MLSC. 

Allurion’s Chairman and CEO Jonathan Wecker said “the Accelerator loan from the MLSC did exactly what we needed – it accelerated our development and allowed us to build a case for traditional private investment.  We are grateful to the MLSC for its early confidence in our potential and are proud to have returned the funds, with interest, to the Commonwealth.”

“Our Accelerator Loan Program seeks to derisk promising earlystage companies and make them more attractive to private investors,” said Massachusetts Life Sciences Center President & CEO Travis McCready.  “We were pleased to provide early financial and workforce support to Allurion, both through our Accelerator Program and our Internship Challenge Program, as they built their company and developed this promising technology.  We look forward to seeing the ongoing positive impact that their technology will have on patients around the world.”

“The biotech sector is thriving across the state, and Allurion is a terrific example of innovation and entrepreneurship here in MetroWest,” said Senator Karen E. Spilka (D-Ashland). “This is a MLSC success story of a targeted investment in the life sciences cluster creating jobs and advancing critical technology. I look forward to continuing the state’s partnership with Allurion and other innovative life sciences companies in our community.”

“It is great to see that the MetroWest continues to be a leader in the research and development of life sciences,” said Representative David Linsky (D-Natick). “I look forward to the future projects that will come out of Allurion.”

SAPA-NE Career Development Symposium Career in Biotech Start-up and Entrepreneurship 
– Translating Research into Business, Ideas/Technology into Pipelines/Products 
MIT Maclaurin Building 4-370 182 Memorial Drive (Rear), Cambridge, MA 02138 
Saturday 1-6 PM, March 18, 2017 

Welcome to attend the 19th SAPA-NE Career Development Symposium on Saturday, March 18th, 2017 at MIT Maclaurin Building. The biopharma industry entrepreneurs and the experts in legal and venture capital will share their experience and perspective in successfully founding, managing or investing in biotech start-up(s) and overall insight and visions on scientific innovation and biotech entrepreneurship. The meeting will also provide the attendees an excellent opportunity to network with biopharmaceutical professionals around Boston area and to access some new job openings posted onsite. The Plenary Session Speakers include: Yi Zhang, Ph.D., a HHMI Investigator and Professor of HMS and BCH, and a co-founder of Epizyme Joy Alamgir, Entrepreneur, Founder, EVP and CSO of Consilience Software, A Xerox Company Chong Xu, Ph.D., Associate, F-Prime Capital Partners, Boston Ruhong Jiang, Ph.D., a co-founder, president and CEO of Applied Stem Cell Fang Xie, Ph.D., Of Counsel, Greenberg Traurig, LLP, Boston Follow by a panel discussion with all speakers plus Wei Zhao, Ph.D., Associate, Wuxi Healthcare Venture Online registration: http://sapa-neweb.org/CDS2017.php This event is free for SAPA-NE members and MIT students; $30 for non-members; $15 for students. (coorganizer MIT-CHIEF) SAPA-NE Career Development Symposium Organizing Committee 

U.S. Department of Homeland Security to Keynote at Biosurveillance Integration,
part of Biodefense World Summit

The national strategy for biosurveillance calls for a coordinated approach for threats to public health and safety, bringing together federal, state and local governments; private sector, nongovernmental organizations and international partners to enhance existing biosurveillance capabilities and develop new ones that provide decision makers and responders with the essential information to manage these threats. This strategy recognizes that a well-integrated national biosurveillance enterprise can save lives by providing essential information for better decision making at all levels. The Sixth Annual Biosurveillance Integration conference will address implementation strategies for the national strategy for biosurveillance identified core functions.
Luther LindlerBiosurveillance to Protect the Homeland
Luther Lindler, Ph.D., Senior Scientist (ST), Biological Programs, Chemical and Biological Defense Division Science and Technology Directorate, U.S. Department of Homeland Security
One of the Department of Homeland Security's (DHS) responsibilities is to protect the U.S. from a biological attack. The Science and Technology Directorate, through the Chemical and Biological Defense Division (CBD), has developed a Real Time Threat Awareness biosurveillance program that integrates information data streams with new detection technologies. This presentation will discuss the interest areas and progress DHS CBD is making toward building a 21st century biosurveillance program.

Dr. Lindler joined the DHS Science and Technology Directorate in October 2003 as a Senior Science Advisor. Dr. Lindler currently serves the Senior Scientist for biological programs within the chemical and biological defense division where he provides expertise to both DOD as well as DHS about current infectious disease threats from a global perspective. He currently serves on the Joint Influenza Surveillance Working Group for DOD, is the DOD representative to the Interagency Influenza Diagnostics Working Group, as well as senior advisor to DOD Health Affairs on technical diagnostic issues that affect force health protection. He currently manages several projects related to infectious disease for the AFHSC. The most notable is to bring forward deployed rapid molecular diagnostics to DOD forward deployed forces. He also serves on the National Biodefense Analysis and Countermeasures Center review committee for DHS S&T and has participated in the national Material Threat Assessment and Biological Risk Assessment programs. His first position within DHS was as the Science Advisor for the NBACC. He helped plan the NBACC forensics and threat characterization programs as well as the first DHS laboratory building on the Fort Detrick National Biodefense Campus. Before joining DHS, Dr. Lindler was a leader in the US Army Biodefense program. He was a principle investigator at the Walter Reed Army Institute of Research leading a team of professionals studying the pathogenesis of the plague bacterium. He served on the Army’s plague vaccine steering committee and the emerging threats steering committee within the Biodefense program. The peak of his career with the Army culminated with his senior editorship of the well-acclaimed Biodefense book entitled, “Biological Weapons Defense; Infectious Diseases and Counterbioterrorism.” Dr. Lindler was a postdoctoral fellow in the laboratory of Dr. Susan Straley at the University of Kentucky in Lexington from 1987 until 1989. Dr. Lindler received his Ph.D. in Microbiology from the Medical College of Virginia in 1987, his Masters of Science in Microbiology from Clemson University in 1981 and his Bachelor’s of Science in Medical Technology from Lenoir Rhyne College in North Carolina in 1978.

WuXi NextCODE Appoints Hannes Smarason as CEO, John Long as CFO, and Alex Fowkes as COO

Appointments bolster global business expansion, operational integration and independent strategic development

WuXi NextCODE 
Feb 28, 2017, 13:00 ET

SHANGHAICAMBRIDGE, Mass. and REYKJAVIK, IcelandFeb. 28, 2017 /PRNewswire/ -- WuXi NextCODE, a WuXi AppTec group company and the contract genomics organization enabling precision medicine worldwide, today announced that the company's chief operating officer Hannes Smarason has been appointed as the company's chief executive officer, and WuXi AppTec senior vice presidents John Long and Alex Fowkes have been named chief financial officer and chief operating officer, respectively.
"WuXi NextCODE is executing on its vision to enable anyone to use the genome to advance health and wellness worldwide," said Dr Ge Li, founder and chairman of WuXi AppTec group and chairman of WuXi NextCODE. "It is also positioning itself as the data management platform at the heart of the genomics revolution and what may become the world's largest data ecosystem. Hannes, John and Alex have the breadth of vision and proven executive capabilities to carry out this strategy and advance the company to the next level."

"This is an exciting time at WuXi NextCODE, as we work on leading projects in every facet of genomics and advance a global standard for the way genomic data is organized, mined and shared," said Mr Smarason. "John and Alex's leadership and experience in life sciences finance and operations, and in the recent independent listing of other WuXi AppTec companies, will be invaluable as we grow our business and forge our own strategic path. We are very pleased to have them join our team and offer them a warm welcome to WuXi NextCODE."
Hannes Smarason co-founded NextCODE Health in 2013 as a spinout from deCODE genetics. He oversaw NextCODE's acquisition by WuXi AppTec in 2015 and its merger with the WuXi Genome Center to create WuXi NextCODE. He served as COO until January 2017 and as CEO will lead the company's overall business and corporate strategy.
John Long has served as WuXi AppTec's senior vice president of finance since 2013. He was actively involved in WuXi AppTec's privatization from NYSE in 2015 and played important roles in WuXi AppTec's subsequent corporate restructuring, supporting WuXi Biologics's recent IPO filing process in Hong Kong as well as private placements in the China capital market. John has over twenty years' experience in financial management, investment and operations in the US, China and Singapore, and prior to joining WuXi AppTec served in senior roles at Willis Group, Tyco International and Lucent Technologies. In addition to finance and operations leadership, he will provide WuXi NextCODE with global expertise in governance, reporting, strategic planning, treasury and tax. John holds a bachelor's degree in economics from the University of International Business and Economics in Beijing and received his MBA from Wharton School of Business at University of Pennsylvania.
Alex Fowkes has twenty years experience in the life science industry in operations, business development, strategy and legal roles. He joined WuXi AppTec in 2012 initially to lead corporate development and then most recently serving as senior vice president of commercial operations. Prior to WuXi Alex served in a variety roles for Pfizer in the US, UK, Australia and China over 14 years.
About WuXi NextCODEWuXi NextCODE is a fully integrated global contract genomics organization. With offices in ShanghaiKendall Square in Cambridge, Massachusetts; and Reykjavik, Iceland, we offer comprehensive services that enable population, precision medicine, diagnostics and wellness initiatives and enterprises to use the genome to improve health around the world. Our capabilities span study design, sequencing, secondary analysis, storage, and interpretation and scalable analytics – all backed by the most proven and widely used technology for organizing, mining and sharing genome sequence data. We are also applying the same capabilities to advance a growing range of sequence-based tests and scans in China. WuXi NextCODE is a WuXi AppTec Group company. Visit us on the web at wuxinextcode.com.